HighLight Capital of Shanghai, a early-stage China healthcare PE firm, is raising $229 million for its second fund; PharmaBlock Sciences, a Nanjing CRO/CMO, will list its shares on China's Third Board and plans to migrate to Shenzhen's GEM Exchange within a year; WuXi AppTec and Shenzhen's Huawei have launched the China Precision Medicine Cloud, a big data project; Jiangsu Hengrui Medicine signed a MOU for China rights to a oncolytic virus therapeutic developed by Japan's Oncolys Biopharma; Sinovac Biotech of Beijing said new government regulations caused China vaccine revenues to fall 50% in Q1; China's FDA is having difficulty retaining experienced staff members because industry jobs often pay five times as much; and OrbusNeich, a vascular device company headquartered in Hong Kong, announced two new products to treat peripheral artery disease.
